Genetic and epigenetic signatures associated with plasma oxytocin levels in children and adolescents with autism spectrum disorder

- Posted in Genetic and epigenetic signatures associated with plasma oxytocin levels in children and adolescents with autism spectrum disorder by English by

This is another study about oxytocin role in autism. It reflects a view of autism as mainly about communication skills. Yet autism's diagnostic is not standardized, and as for some other diseases biomarkers are actively seeked as hopes for a genetic origin have been dashed.

Oxytocin (OT), the brain's most abundant neuropeptide, plays an important role in social salience and motivation. Studies have looked at oxytocin's role in various behaviors, including orgasm, social recognition, pair bonding, anxiety, in-group bias, autism, and maternal behaviors.

As Oxytocin is believed to have a significant role in social learning, it has been implicated in the etiology of autism, with one report suggesting autism is correlated to a mutation on the oxytocin receptor gene (OXTR). Low levels of oxytocin could become a new biomarker for individuals that fall into the Autism Spectrum.

Yet clinical trials of the efficacy of oxytocin in autism spectrum disorder (ASD) have reported mixed results due in part to autism spectrum disorder complex etiology. The scientists here hypothesized that genetic and epigenetic variation contribute to variable endogenous oxytocin levels that modulate sensitivity to oxytocin therapy.

To test this hypothesis, the authors integrated genome-wide profiles of DNA-methylation, transcriptional activity, and genetic variation with plasma oxytocin levels in 290 participants with autism spectrum disorder enrolled in a randomized controlled trial of oxytocin.

Their analysis shows subtle, but statistically significant association of plasma oxytocin levels with peripheral transcriptional activity and DNA-methylation profiles across several annotated gene sets. The scientists also identified genetic variants with novel association with plasma oxytocin, several of which reside in known autism spectrum disorder risk genes.

These findings broaden authors' understanding of the effects of the peripheral oxytocin system and provide novel genetic candidates for future studies to decode the complex etiology of autism spectrum disorder and its interaction with oxytocin signaling and oxytocin-based interventions.

Read the original article on medRxiv

Does the Heart Fall Asleep? - Diurnal Variations of Heart Rate Variability in Patients with Disorders of Consciousness

- Posted in Does the Heart Fall Asleep? - Diurnal Variations of Heart Rate Variability in Patients with Disorders of Consciousness by English by

The current study investigated heart rate (HR) and heart rate variability (HRV) across day and night in patients with disorders of consciousness (DOC). the authors recorded 24-h ECG in 26 patients with unresponsive wakefulness syndrome (UWS) and (exit) minimally conscious state ((e)MCS).

A persistent vegetative state or post-coma unresponsiveness is a disorder of consciousness in which patients with severe brain damage are in a state of partial arousal rather than true awareness. After four weeks in a vegetative state, the patient is classified as in a persistent vegetative state.

A minimally conscious state is a disorder of consciousness distinct from persistent vegetative state and locked-in syndrome. Unlike persistent vegetative state, patients with minimally conscious state have partial preservation of conscious awareness.

To examine diurnal variations, HR and HRV indices in the time, frequency, and entropy domains were computed for periods of clear day and nighttime.

Results indicate that patients interbeat intervals (IBIs) were larger during the night than during the day indicating heart rate slowing. Additionally, higher heart rate variability entropy was associated with higher EEG entropy during the night. Patients in unresponsive wakefulness syndrome showed larger interbeat intervals compared to patients in minimally conscious state, and patients with non-traumatic brain injury showed lower ECG entropy than patients with traumatic brain injury.

Thus, cardiac activity varies with a diurnal pattern in patients with disorder of consciousness and can differentiate between patients diagnoses and etiologies. Moreover, also the interaction of heart and brain appears to follow a diurnal rhythm.

Thus, heart rate and heart rate variability seem to mirror the integrity of brain functioning and consequently might serve as supplementary measures for improving the validity of assessments in patients with disorder of consciousness.

Read the original article on medRxiv

Ropinirole extends survival by 28 weeks in an ALS clinical trial.

- Posted in Ropinirole extends survival by 28 weeks in an ALS clinical trial. by English by

Some years ago there were great hopes in Pramipexole hydrochloride, a dopamine agonist. A phase III, multicenter, randomized, double-blind, placebo-controlled study of RPPX (EMPOWER) was conducted in ALS patients in the US, Canada, Australia, and Europe; however, regrettably, the results were clinically insignificant.

In 2018 Japanese scientists used induced pluripotent stem cell (iPSC) technology to generate stem and differentiated cells retaining the patients' full genetic information. They thus established a large number of in vitro cellular models of SALS. These models showed phenotypic differences in their pattern of neuronal degeneration, types of abnormal protein aggregates, cell death mechanisms, and onset and progression of these phenotypes in vitro among cases.

The researchers therefore developed a system for case clustering capable of subdividing these heterogeneous SALS models by their in vitro characteristics. They further evaluated multiple-phenotype rescue of these subclassified SALS models using agents selected from non-SOD1 FALS models, and identified ropinirole, a drug similar to Pramipexole, as a potential therapeutic candidate.

As a result, ropinirole hydrochloride was eventually selected. Therefore, the scientists wanted to explore the safety, tolerability and efficacy of ropinirole hydrochloride as an ALS treatment in this clinical trial.

Patient recruitment began in December 2018 and the scientists published their results on MedArXiv. Twenty one participants with Amyotrophic Lateral Sclerosis FRS-R scores greater than 2 points were randomly assigned using dynamic allocation to receive ropinirole or placebo for 24 weeks in the double-blind period.

enter image description here

Upon completion, participants could choose to participate in the following 24-week open-label active extension period. The primary outcomes were safety and tolerability. The secondary outcomes for the feasibility trial objective were the change in the ALS FRS-R) score, composite functional endpoint, combined assessment of function and survival, event-free survival, and time to [≤]50% forced vital capacity (blinded outcome assessment).

The participants were randomized into two groups (ropinirole group; n=14) and received ropinirole (n=13) or placebo (n=7) and the data of all participants were analysed using mixed-effects models for repeated measures together.

The incidence of gastrointestinal disorders (mainly, temporary mild nausea and diarrhoea) was high at 77% in the ropinirole group versus 14% in the placebo group). This is common in this type of clinical trial yet it is a major problem to keep long term adherence to the treatment.

Regarding the feasibility of verifying efficacy, there were no significant differences in the ALS FRS-R score and combined assessment of function and survival scores during the double-blind period for 6 months, while the participants in the ropinirole group had lived an additional 28 weeks without disease progression events compared with the placebo group at 12 months. It seems the effect of ropinorole became obvious only after 24 weeks. enter image description here

Ropinirole is thus found (by the authors) safe and tolerable for patients with ALS and this trial indicates feasibility for a subsequent large-scale trial.

Read the original article on medRxiv

Contact the author

Advertisement


This book retraces the main achievements of ALS research over the last 30 years, presents the drugs under clinical trial, as well as ongoing research on future treatments likely to be able stop the disease in a few years and to provide a complete cure in a decade or two.

In Silico Computer Models for Deep Brain Stimulation

- Posted in In Silico Computer Models for Deep Brain Stimulation by English by

Deep brain stimulation (DBS) is an established therapy for patients with Parkinson's disease. enter image description here In silico computer models for DBS allow to pre-select a set of potentially optimal stimulation parameters. If efficacious, they could further carry insight into the mechanism of action of DBS and foster the development of more efficient stimulation approaches. In recent years, the focus has shifted towards DBS-induced firing in myelinated axons, deemed particularly relevant for the external modulation of neural activity.

The scientists in this new medRxiv publication, use the concept of pathway activation modeling, which incorporates advanced volume conductor models and anatomically authentic fiber trajectories to estimate DBS-induced action potential initiation in anatomically plausible pathways that traverse in close proximity to targeted nuclei.

Then the scientists applied the method on a retrospective dataset with the aim of providing a model-based prediction of clinical improvement following DBS (as measured by the motor part of the Unified Parkinsons Disease Rating Scale).

Based on differences in outcome and activation rates for two DBS protocols in a training cohort, the authors computed a theoretical 100% improvement profile and enhanced it by analyzing the importance of profile matching for individual pathways.

Finally, the authors validated the performance of authors' profile-based predictive model in a test cohort.

As a result, the authors demonstrated the clinical utility of pathway activation modeling in the context of motor symptom alleviation in Parkinsons patients treated with DBS.

Read the original article on medRxiv


Please, help us continue to provide valuable information: